Enhanced prostacyclin availability of blood vessels in uraemic humans and rats.
Recently prostacyclin (PHI2), an unstable prostaglandin with a strong inhibitory effect on platelet aggregation, has been demonstrated in the wall of blood vessels. We estimated the PGI2 availability of arteries and veins in 10 uraemic patients and 12 nephrectomised rats. The production of PGI2 after long-term incubation of the vessels was markedly enhanced and prolonged. This alteration is probably one key mechanism for the deterioration of haemostasis in uraemics. Preliminary results of further studies indicate that substances in uraemic plasma--presumably middle molecules--may enhance the PGI2 availability of normal vessels in vitro.
D000818:Animals; D001158:Arteries / Q000378:metabolism*; D011464:Epoprostenol / Q000378:metabolism* / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects; D011453:Prostaglandins / Q000378:metabolism*; D051381:Rats; D014118:Toxins, Biological / Q000097:blood; D014511:Uremia / Q000097:blood / Q000378:metabolism*; D014680:Veins / Q000378:metabolism*
D011453:Prostaglandins; D014118:Toxins, Biological; D011464:Epoprostenol